Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/6/941 |
| _version_ | 1797472379202437120 |
|---|---|
| author | Jianbiao Zhou Wee-Joo Chng |
| author_facet | Jianbiao Zhou Wee-Joo Chng |
| author_sort | Jianbiao Zhou |
| collection | DOAJ |
| description | Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors. |
| first_indexed | 2024-03-09T20:01:58Z |
| format | Article |
| id | doaj.art-7aa2ac8d1489429e9212ffa4eded76a6 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T20:01:58Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-7aa2ac8d1489429e9212ffa4eded76a62023-11-24T00:43:37ZengMDPI AGCells2073-44092022-03-0111694110.3390/cells11060941Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaJianbiao Zhou0Wee-Joo Chng1Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, SingaporeCancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, SingaporeMultiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.https://www.mdpi.com/2073-4409/11/6/941multiple myelomasignal transducer and activator of transcription 3 (STAT3)hallmarks of cancertargeted therapyJAK inhibitor |
| spellingShingle | Jianbiao Zhou Wee-Joo Chng Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma Cells multiple myeloma signal transducer and activator of transcription 3 (STAT3) hallmarks of cancer targeted therapy JAK inhibitor |
| title | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma |
| title_full | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma |
| title_fullStr | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma |
| title_full_unstemmed | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma |
| title_short | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma |
| title_sort | biological hallmarks and emerging strategies to target stat3 signaling in multiple myeloma |
| topic | multiple myeloma signal transducer and activator of transcription 3 (STAT3) hallmarks of cancer targeted therapy JAK inhibitor |
| url | https://www.mdpi.com/2073-4409/11/6/941 |
| work_keys_str_mv | AT jianbiaozhou biologicalhallmarksandemergingstrategiestotargetstat3signalinginmultiplemyeloma AT weejoochng biologicalhallmarksandemergingstrategiestotargetstat3signalinginmultiplemyeloma |